Our webinars allow users to learn from experts and earn continuing education credits on industry topics, progress in research, services available, and more.
Identification of actionable mutations, determination of tumor mutational burden (TMB) and microsatellite (MS) status are paramount to precision oncology and the Oncomine Comprehensive Assay...
During the presentation, Dr. Hernandez-Losa will describe the experience in the Department of Pathology using NGS with S5-xl in different translational projects in solid tumors. Additionally...
During the presentation, Dr. Hernandez-Losa will describe the experience in the Department of Pathology using NGS with S5-xl in different translational projects in solid tumors. Additionally...
Myeloid neoplasms are a group of heterogeneus disorders originating from the neoplastic transformation of a pluripotent hematopoietic progenitor cell. Following the acquisition of somatic mu...
Myeloid neoplasms are a group of heterogeneus disorders originating from the neoplastic transformation of a pluripotent hematopoietic progenitor cell. Following the acquisition of somatic mu...
Precision oncology is revolutionizing the diagnostic and therapeutic approach to cancer. In fact, the availability of tumor-specific and tumor-agnostic biomarkers and matched therapies is ra...
Precision oncology is revolutionizing the diagnostic and therapeutic approach to cancer. In fact, the availability of tumor-specific and tumor-agnostic biomarkers and matched therapies is ra...
The treatment of cancer has remarkably improved because of increased knowledge of the molecular abnormalities that drive human cancer growth. This has led to the development of ever more eff...
The treatment of cancer has remarkably improved because of increased knowledge of the molecular abnormalities that drive human cancer growth. This has led to the development of ever more eff...
Comprehensive genomic profiling in clinical research studies helps to detect clinically relevant cancer driver mutations using low amount of tumor tissues within several days. Recent studies...
Comprehensive genomic profiling in clinical studies helps to detect clinically relevant cancer driver mutations using low amount of tumor tissues within several days. Recent studies have sho...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
Date: October 21, 2020 Time: 8:00am PDT Learning Objectives Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provider of continuing educ...
DATE: October 20th, 2020 TIME: 08:00am PT, 11:00am ET Tumor-associated macrophages (TAMs) are key cells in the tumor microenvironment (TME) with diverse immune functions that have a major in...
Date: October 20, 2020 Time: 5:00am (PDT), 8:00am (EDT), 2:00pm (CEST) With the COVID-19 pandemic as one of the biggest challenges to our modern world, Bruker has taken an active part suppor...
Date: October 15, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Renal transporters play an important role in potential clinical drug-drug interactions (DDIs) as highlighted in the FDA, EMA and PMDA...
DATE: October 15, 2020 TIME: 8am PDT, 11am EDT Density gradient centrifugation is an effective method for the isolation and purification of small particles. Hollow rotors capable of hosting...
DATE: October 14, 2020 TIME: 10:00am PT Do you need help in planning your drug testing protocols? Did you know that a “one size fits all” approach to drug testing does not apply...
Date: September 16, 2020 Time: 7:00am (PDT), 10:00am (EDT) Of the 15 million patients admitted to US based hospitals with medical, non-surgical illnesses, 8 million possess inherent risk of...
Date: October 13, 2020 Time: 5:00am (PDT), 8:00am (EDT) Dr. Markus Kostrzewa shall ellaborate the progress that has been made in Bruker Microbiology Research and Development, including new p...